Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v18-FR Version v18-FR
Language French French
Date Updated 2023-04-06 2023-04-06
Drug Identification Number 00896187 00896187
Brand name SODIUM PHOSPHATES INJECTION USP SODIUM PHOSPHATES INJECTION USP
Common or Proper name SODIUM PO4 SODIUM PO4
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients SODIUM PHOSPHATE DIBASIC SODIUM PHOSPHATE MONOBASIC SODIUM PHOSPHATE DIBASIC SODIUM PHOSPHATE MONOBASIC
Strength(s) 268MG 276MG 268MG 276MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 10ML 10LIVI 10ML 10LIVI
ATC code B05XA B05XA
ATC description I.V. SOLUTION ADDITIVES I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-02-20 2023-02-20
Estimated end date 2023-04-03 2023-04-03
Actual end date 2023-04-03 2023-04-03
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Baxter item : 7990 Baxter item : 7990
Health Canada comments